[{"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: BBV152: 0.5 mL Vero cell derived inactivated vaccine containing NLT 6\u00ce\u00bcg andadministered as a single dose intramuscularly (IM)Intervention2: BBV154: BBV154 is a liquid; Adenoviral vector-based (expressing a stabilized spike protein) SARS-CoV-2 vaccine (BBV154) administered as intranasal route (nasal drop)Control Intervention1: NA: NA", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: BBV152: 0.5 mL Vero cell derived inactivated vaccine containing NLT 6\u00ce\u00bcg andadministered as a single dose intramuscularly (IM)", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention2: BBV154: BBV154 is a liquid; Adenoviral vector-based (expressing a stabilized spike protein) SARS-CoV-2 vaccine (BBV154) administered as intranasal route (nasal drop)", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Control Intervention1: NA: NA", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "2;Days0-28;IM", "treatment_id": 1387, "treatment_name": "Covaxin", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "1+1;Day0 (BBV152)+Day28(BBV154);Heterologous prime-boost", "treatment_id": 1897, "treatment_name": "Bbv154+covaxin", "treatment_type": "Non replicating viral vector+inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "1+1;Day0 (BBV154)+Day28(BBV152);Heterologous prime-boost", "treatment_id": 1897, "treatment_name": "Bbv154+covaxin", "treatment_type": "Non replicating viral vector+inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "2;Days0-28;IN", "treatment_id": 185, "treatment_name": "Bbv154", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "N/A", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: BBV152: 0.5 mL Vero cell derived inactivated vaccine containing NLT 6\u00ce\u00bcg andadministered as a single dose intramuscularly (IM)Intervention2: BBV154: BBV154 is a liquid; Adenoviral vector-based (expressing a stabilized spike protein) SARS-CoV-2 vaccine (BBV154) administered as intranasal route (nasal drop)Control Intervention1: NA: NA", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: BBV152: 0.5 mL Vero cell derived inactivated vaccine containing NLT 6\u00ce\u00bcg andadministered as a single dose intramuscularly (IM)", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention2: BBV154: BBV154 is a liquid; Adenoviral vector-based (expressing a stabilized spike protein) SARS-CoV-2 vaccine (BBV154) administered as intranasal route (nasal drop)", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Control Intervention1: NA: NA", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]